12:00 AM
 | 
Mar 09, 2015
 |  BC Week In Review  |  Company News  |  Deals

Amgen, Celimmune deal

Amgen granted Celimmune exclusive, ex-Japan rights to develop and commercialize AMG 714. Celimmune is planning Phase II trials of the human mAb against IL-15 to treat diet...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >